Neoadjuvant Therapy

"Neoadjuvant Therapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, immunotherapy, hyperthermia, etc.) that precedes a necessary second modality of treatment.

Descriptor ID	D020360
MeSH Number(s)	E02.186.450
Concept/Terms	Neoadjuvant Therapy Neoadjuvant Therapy Neoadjuvant Therapies Therapies, Neoadjuvant Therapy, Neoadjuvant Neoadjuvant Treatment Neoadjuvant Treatments Treatment, Neoadjuvant Treatments, Neoadjuvant

Below are MeSH descriptors whose meaning is more general than "Neoadjuvant Therapy".

Analytical, Diagnostic and Therapeutic Techniques and Equipment [E]
Therapeutics [E02]
Combined Modality Therapy [E02.186]
Neoadjuvant Therapy [E02.186.450]

Below are MeSH descriptors whose meaning is related to "Neoadjuvant Therapy".

Below are MeSH descriptors whose meaning is more specific than "Neoadjuvant Therapy".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Neoadjuvant Therapy" by people in this website by year, and whether "Neoadjuvant Therapy" was a major or minor topic of these publications.

Bar chart showing 72 publications over 21 distinct years, with a maximum of 7 publications in 2019 and 2022

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2002	1	0	1
2005	0	1	1
2007	1	2	3
2008	0	3	3
2009	0	1	1
2010	1	2	3
2011	2	2	4
2012	1	3	4
2013	2	2	4
2014	1	2	3
2015	0	1	1
2016	3	0	3
2017	1	2	3
2018	1	4	5
2019	1	6	7
2020	1	3	4
2021	5	1	6
2022	2	5	7
2023	0	4	4
2024	4	0	4
2025	1	0	1

Below are the most recent publications written about "Neoadjuvant Therapy" by people in Profiles.

Donovan KF, Tomada EP, Carmichael H, Ricardo A, Berger N, Bonaccorso A, Alavi K, Zaghiyan K, Pigazzi A, Sands D, DeBeche-Adams T, Chadi SA, McLemore EC, Marks JH, Maykel JA, Shawki SF, Steele SR, Albert M, Whiteford MH, Wexner SD, Sylla P. Impact of neoadjuvant treatment on functional outcomes after transanal total mesorectal excision (taTME)-a case series. Surg Endosc. 2025 Oct; 39(10):6802-6812.

View in: PubMed
Davar D, Morrison RM, Dzutsev AK, Karunamurthy A, Chauvin JM, Amatore F, Deutsch JS, Das Neves RX, Rodrigues RR, McCulloch JA, Wang H, Hartman DJ, Badger JH, Fernandes MR, Bai Y, Sun J, Cole AM, Aggarwal P, Fang JR, Deitrick C, Bao R, Duvvuri U, Sridharan SS, Kim SW, A Choudry H, Holtzman MP, Pingpank JF, O'Toole JP, DeBlasio R, Jin Y, Ding Q, Gao W, Groetsch C, Pagliano O, Rose A, Urban C, Singh J, Divarkar P, Mauro D, Bobilev D, Wooldridge J, Krieg AM, Fury MG, Whiteaker JR, Zhao L, Paulovich AG, Najjar YG, Luke JJ, Kirkwood JM, Taube JM, Park HJ, Trinchieri G, Zarour HM. Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial. Cancer Cell. 2024 Nov 11; 42(11):1898-1918.e12.

View in: PubMed
Bauer PS, Gamboa AC, Otegbeye EE, Chapman WC, Rivard S, Regenbogen S, Hrebinko KA, Holder-Murray J, Wiseman JT, Ejaz A, Edwards-Hollingsworth K, Hawkins AT, Hunt SR, Balch GC, Wise PE. Short-Course TNT Improves Rectal Tumor Downstaging in a Retrospective Study of the US Rectal Cancer Consortium. J Surg Oncol. 2025 Mar; 131(3):498-506.

View in: PubMed
Shatsky RA, Trivedi MS, Yau C, Nanda R, Rugo HS, Davidian M, Tsiatis B, Wallace AM, Chien AJ, Stringer-Reasor E, Boughey JC, Omene C, Rozenblit M, Kalinsky K, Elias AD, Vaklavas C, Beckwith H, Williams N, Arora M, Nangia C, Roussos Torres ET, Thomas B, Albain KS, Clark AS, Falkson C, Hershman DL, Isaacs C, Thomas A, Tseng J, Sanford A, Yeung K, Boles S, Chen YY, Huppert L, Jahan N, Parker C, Giridhar K, Howard FM, Blackwood MM, Sanft T, Li W, Onishi N, Asare AL, Beineke P, Norwood P, Brown-Swigart L, Hirst GL, Matthews JB, Moore B, Symmans WF, Price E, Heditsian D, LeStage B, Perlmutter J, Pohlmann P, DeMichele A, Yee D, van 't Veer LJ, Hylton NM, Esserman LJ. Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Nat Med. 2024 Dec; 30(12):3737-3747.

View in: PubMed
Khoury K, Meisel JL, Yau C, Rugo HS, Nanda R, Davidian M, Tsiatis B, Chien AJ, Wallace AM, Arora M, Rozenblit M, Hershman DL, Zimmer A, Clark AS, Beckwith H, Elias AD, Stringer-Reasor E, Boughey JC, Nangia C, Vaklavas C, Omene C, Albain KS, Kalinsky KM, Isaacs C, Tseng J, Roussos Torres ET, Thomas B, Thomas A, Sanford A, Balassanian R, Ewing C, Yeung K, Sauder C, Sanft T, Pusztai L, Trivedi MS, Outhaythip A, Li W, Onishi N, Asare AL, Beineke P, Norwood P, Brown-Swigart L, Hirst GL, Matthews JB, Moore B, Fraser Symmans W, Price E, Beedle C, Perlmutter J, Pohlmann P, Shatsky RA, DeMichele A, Yee D, van 't Veer LJ, Hylton NM, Esserman LJ. Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Nat Med. 2024 Dec; 30(12):3728-3736.

View in: PubMed
Zager Y, Horesh N, Abdelmasseh M, Aquina CT, Alfonso BLL, Soliman MK, Albert MR, Monson JRT. The predicting value of post neoadjuvant treatment magnetic resonance imaging: a meta-analysis. Surg Endosc. 2024 Nov; 38(11):6846-6853.

View in: PubMed
Switalla KM, Boughey JC, Dimitroff K, Yau C, Ladores V, Yu H, Tchou J, Golshan M, Ahrendt G, Postlewait LM, Piltin M, Reyna CR, Matsen CB, Tuttle TM, Wallace AM, Arciero CA, Lee MC, Tseng J, Son J, Rao R, Sauder C, Naik A, Howard-McNatt M, Lancaster R, Norwood P, Esserman LJ, Mukhtar RA. Clipping the Positive Lymph Node in Patients with Clinically Node Positive Breast Cancer Treated with Neoadjuvant Chemotherapy: Impact on Axillary Surgery in the ISPY-2 Clinical Trial. Ann Surg Oncol. 2024 Oct; 31(11):7249-7259.

View in: PubMed
Piltin MA, Norwood P, Ladores V, Mukhtar RA, Sauder CA, Golshan M, Tchou J, Rao R, Lee MC, Son J, Reyna C, Hewitt K, Kuerer H, Ahrendt G, Greenwalt I, Tseng J, Postlewait L, Howard-McNatt M, Jaskowiak N, Esserman LJ, Boughey JC. Internal Mammary Lymphadenopathy Does Not Impact Oncologic Outcomes in Patients Treated with Neoadjuvant Chemotherapy: Results from the I-SPY2 Clinical Trial. Ann Surg Oncol. 2024 Oct; 31(11):7420-7428.

View in: PubMed
Benjamin WJ, Feng AL, Heft Neal M, Bellile E, Casper KA, Malloy KM, Rosko AJ, Stucken CL, Prince ME, Mierzwa ML, Taylor JMG, Eisbruch A, Spector ME, Wolf GT, Swiecicki PL, Worden FP, Chinn SB. Utility of bioselection with neoadjuvant chemotherapy for organ preservation in patients with T4 laryngeal cancer. Oral Oncol. 2024 Sep; 156:106917.

View in: PubMed
Bauer PS, Gamboa AC, Otegbeye EE, Chapman WC, Rivard S, Regenbogen S, Mohammed M, Holder-Murray J, Wiseman JT, Ejaz A, Edwards-Hollingsworth K, Hawkins AT, Hunt SR, Balch G, Silviera ML. Short-course radiation with consolidation chemotherapy does not increase operative morbidity compared to long-course chemoradiation: A retrospective study of the US rectal cancer consortium. J Surg Oncol. 2024 Feb; 129(2):254-263.

View in: PubMed

People

Explore

Similar Concepts

Top Journals